Verona Pharma plc (NASDAQ:VRNA) to Post FY2025 Earnings of ($1.20) Per Share, HC Wainwright Forecasts

Verona Pharma plc (NASDAQ:VRNA) – Equities researchers at HC Wainwright raised their FY2025 earnings estimates for Verona Pharma in a report released on Tuesday, September 17th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($1.20) for the year, up from their previous forecast of ($1.28). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Verona Pharma’s current full-year earnings is ($2.07) per share.

Verona Pharma (NASDAQ:VRNA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.53). During the same quarter in the prior year, the firm earned ($0.11) EPS.

A number of other brokerages have also issued reports on VRNA. Canaccord Genuity Group upped their target price on shares of Verona Pharma from $35.00 to $37.00 and gave the company a “buy” rating in a research note on Monday, July 22nd. Truist Financial lifted their target price on Verona Pharma from $32.00 to $38.00 and gave the company a “buy” rating in a research note on Friday, June 28th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $36.00.

Verona Pharma Stock Performance

Verona Pharma stock opened at $29.40 on Thursday. Verona Pharma has a 52 week low of $11.39 and a 52 week high of $30.73. The company has a current ratio of 8.61, a quick ratio of 8.61 and a debt-to-equity ratio of 0.72. The stock has a market cap of $2.39 billion, a P/E ratio of -38.18 and a beta of 0.44. The stock has a 50 day moving average of $25.28 and a 200-day moving average of $18.66.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Maverick Capital Ltd. grew its stake in shares of Verona Pharma by 74.2% in the 2nd quarter. Maverick Capital Ltd. now owns 3,092,807 shares of the company’s stock worth $44,722,000 after purchasing an additional 1,316,998 shares during the last quarter. Candriam S.C.A. bought a new stake in Verona Pharma in the second quarter worth approximately $11,177,000. Eventide Asset Management LLC increased its position in Verona Pharma by 62.1% during the fourth quarter. Eventide Asset Management LLC now owns 1,377,781 shares of the company’s stock worth $27,390,000 after buying an additional 527,781 shares during the last quarter. NEA Management Company LLC raised its stake in shares of Verona Pharma by 9.3% in the 2nd quarter. NEA Management Company LLC now owns 5,584,753 shares of the company’s stock valued at $80,756,000 after acquiring an additional 476,190 shares in the last quarter. Finally, American Century Companies Inc. boosted its holdings in shares of Verona Pharma by 56.6% during the 2nd quarter. American Century Companies Inc. now owns 878,043 shares of the company’s stock worth $12,697,000 after buying an additional 317,184 shares during the period. 85.88% of the stock is currently owned by institutional investors.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.